Results 11 to 20 of about 2,471 (170)

LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling

open access: yesMolecular Cancer, 2023
Lung cancer is the leading cause of cancer-related deaths worldwide. Long non-coding RNAs (lncRNAs) have emerged as key regulators of cancer development and progression, and as promising biomarkers for the diagnosis and prognosis of cancer. In this study,
Qiurong Yang   +9 more
exaly   +4 more sources

An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability [PDF]

open access: yesNature Communications, 2021
Neuroblastoma (NB) is often driven by MYCN amplification. Here, the authors show that the most frequent genetic lesion, gain of 17q21-ter in NB leads to overexpression of ALYREF, which forms a complex with MYCN, regulating MYCN stability via the ...
Janith Ananda Seneviratne   +2 more
exaly   +5 more sources

Hypoxia Triggers ALYREF‐Mediated m5C Methylation of KIF20A to Activate KIF20A/BUB1 for Generating Ferroptosis Resistance in Cervical Cancer Cells [PDF]

open access: yesKaohsiung Journal of Medical Sciences
Ferroptosis resistance is a key player in cervical cancer (CC) development. Hypoxia is a negative factor affecting CC treatment by inducing ferroptosis resistance.
Yan Gao, Ting Zou
doaj   +3 more sources

ALYREF recruits ELAVL1 to promote colorectal tumorigenesis via facilitating RNA m5C recognition and nuclear export

open access: yesNpj Precision Oncology
ALYREF can recognize 5-methylcytosine (m5C) decoration throughout RNAs to regulate RNA metabolism. However, its implications in cancer and precise regulatory mechanisms remain largely elusive. Here, we demonstrated that ALYREF supported colorectal cancer
Longhua Zhong   +6 more
exaly   +4 more sources

ALYREF promotes the metastasis of nasopharyngeal carcinoma by increasing the stability of NOTCH1 mRNA

open access: yesCell Death and Disease
Approximately 70% of treatment failures in nasopharyngeal carcinoma (NPC) patients are attributed to distant metastasis, yet the underlying mechanisms remain unclear.
Ya-Nan Jin
exaly   +4 more sources

ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression

open access: yesSignal Transduction and Targeted Therapy, 2023
Chen Xue   +9 more
exaly   +4 more sources

RNA binding protein ALYREF regulates ferroptosis to facilitate LUAD growth and metastasis via promoting SLC7A11 mRNA stability [PDF]

open access: yesScientific Reports
Ferroptosis is of great significance in carcinogenesis as it interconnects with a multiplicity of biological processes. Meanwhile, its function and regulatory role in lung cancer remains ambiguous.
Yanni Chen   +4 more
doaj   +4 more sources

ALYREF associated with immune infiltration is a prognostic biomarker in hepatocellular carcinoma

open access: yesTranslational Oncology, 2022
Background: Although ALYREF has been demonstrated to have a role in a number of malignancies, its role in hepatocellular carcinoma (HCC) has received little attention.
Zhen-Zhen Wang   +10 more
doaj   +3 more sources

Incomplete activation of Alyref and Gabpb1 leads to preimplantation arrest in cloned mouse embryos

open access: yesLife Science Alliance, 2023
This study shows that failed activation of developmentally required Alyref and Gabpb1 genes leads to the arrest of cloned mouse embryos. Differentiated cell nuclei can be reprogrammed after nuclear transfer (NT) to oocytes and the produced NT embryos can
Shunya Ihashi   +16 more
doaj   +3 more sources

ALYREF inhibits ferroptosis in vascular endothelial cells and improves atherosclerosis by epigenetic modification of CISD1 [PDF]

open access: yesClinical Epigenetics
Background Atherosclerosis (AS) is a disease marked by lipid metabolism dysfunction. Methylation of 5-methylcytosine (m5C) mRNA can regulate AS progression. We investigated the role and mechanism of m5C reader ALYREF in AS. Methods ApoE−/− mice AS models
Jinghai Hua   +7 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy